Peripheral Drug Eluting Balloons Market to Reach USD 1.9 Billion by 2033 with an 8.6% CAGR | Persistence Market Research

The global peripheral drug eluting balloons market stood at US$ 808.2 million in 2022 and is projected to grow at a CAGR of 8.6%, reaching US$ 1.9 billion by 2033. Peripheral drug-eluting balloons (DEBs) are advanced medical devices used to treat arterial blockages. These balloons combine angioplasty with localized drug delivery to prevent restenosis. The paclitaxel drug coating segment dominated in 2022, holding a 47.8% market share. Geographically, North America leads due to the high prevalence of peripheral arterial disease (PAD) and a well-developed healthcare infrastructure.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response):
https://www.persistencemarketresearch.com/samples/27211

Key Highlights from the Report

The market is expected to expand at 8.6% CAGR between 2023 and 2033.

Paclitaxel-coated DEBs accounted for 47.8% market share in 2022.

Peripheral drug eluting balloons contributed 17.2% revenue share in the global peripheral vascular devices market.

Rising geriatric population and increasing prevalence of PAD are major market growth drivers.

The U.S. holds 36.2% of the global market due to a growing number of PAD cases.

Favorable government policies in China are driving market growth in the Asia-Pacific region.

Market Segmentation

Peripheral drug eluting balloons are categorized based on drug coating type, application, and end-user. The paclitaxel drug coating segment holds the largest market share due to its effectiveness in preventing arterial restenosis. The primary application of DEBs is in treating peripheral arterial disease (PAD), which accounted for 37.8% of the market in 2022. Hospitals, ambulatory surgical centers, and specialty clinics are the key end-users driving product demand.

Regional Insights

North America:

North America dominates the market, driven by a high prevalence of PAD, rising healthcare expenditure, and advanced treatment facilities. The United States alone accounted for 36.2% of global revenue in 2022.

Asia-Pacific:

China is emerging as a lucrative market due to favorable reimbursement policies and increased government healthcare investments. Additionally, partnerships between local and international players are expanding the availability of DEBs.

Market Dynamics

Market Drivers:

Rising Aging Population: Older adults are more susceptible to vascular diseases, increasing demand for interventional cardiology procedures.

Increasing Prevalence of PAD: A significant rise in PAD cases, particularly in diabetic and hypertensive patients, is driving market growth.

Technological Advancements: Continuous innovation in drug-coating technologies and catheter materials enhances device efficiency.

Market Restraints:

High Product Costs: DEBs are expensive compared to conventional balloon angioplasty, limiting adoption in cost-sensitive markets.

Limited Long-Term Clinical Data: Healthcare providers require extensive clinical validation before fully integrating DEBs into standard treatments.

Market Opportunities:

Expansion in Emerging Markets: Developing nations are investing heavily in healthcare infrastructure, providing opportunities for market expansion.

Strategic Collaborations: Companies are engaging in mergers and acquisitions to strengthen product portfolios and geographical reach.

Reasons to Buy the Report

✔ Provides in-depth analysis of market size, growth trends, and competitive landscape.
✔ Highlights key drivers, restraints, and opportunities affecting market growth.
✔ Offers detailed segmentation based on product type, application, and end-user industries.
✔ Includes regional insights on market performance in North America, Europe, and Asia-Pacific.
✔ Covers recent developments and innovations in drug-eluting balloon technology.

Company Insights

Leading players in the market include:

BD (Becton, Dickinson and Company)

Medtronic

Boston Scientific Corporation

Terumo Corporation

Cardionovum GmbH

Recent Developments:

In August 2022, BD initiated the first-in-human trial for a new drug-coated balloon (DCB) aimed at treating femoropopliteal arterial disease.

In June 2018, Terumo received CE approval for its drug-coated balloon catheter 'Kanshas' for lower extremity PAD treatment.

The market for peripheral drug eluting balloons is set for robust growth, driven by increasing prevalence of PAD, technological advancements, and supportive healthcare policies worldwide.

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.